Kemisk, bioteknologisk og farmaceutisk industri

Medical Market Access refererer til barrierer der findes i et land, ved introduktion af nye lægemidler til behandling af patienter. Denne lærebog introducerer læseren til medicinsk markedsadgang med stærkt fokus på Danmark og det danske marked for lægemidler; det beskriver karakteristika for det danske marked for lægemidler og dets interessenter og processerne af markedsgodkendelse og godtgørelse. Bogen tager også et virksomhedsperspektiv og forklarer hvordan branchen arbejder med medicinske markedsadgangsproblemer på dansk daglig praksis. For at sætte det danske marked i perspektiv forklares bogen også både samfundsmæssige dilemmaer og internationale medicinske markedsforhold. Bogen er udarbejdet til kandidat-niveau, men selve forståelsen af de nationale og internationale spørgsmål om medicinsk markedsadgang er i stigende grad vigtigt for både fagfolk, der arbejder i sundhedssystemet og den medicinske industri. Denne bog er den første af sin art, der introducerer et udviklende område af betydning ikke kun for industrien som helhed, men også for udbydere, patienter, investorer og tilsynsorganer i Danmark. Lars Holger Ehlers, Ph.D., er professor på the Danish Center for Healthcare Improvements, Institut for Erhverv og Ledelse, Aalborg Universitet. Han har skrevet et stort antal artikler om sundhedsøkonomi og underviser kurser på Aalborg Universitet.

En præcis og opslagsvenlig guide til brug af lægemidler i praksis – nu i 3. udgave."Praktisk farmakologi" henvender sig til den sundhedsprofessionelle, der har brug for et overblik over den praktiske brug af receptpligtige lægemidler og håndkøbslægemidler – særligt farmaceutstuderende og farmakonomer, men også hjemmesygeplejersker, medicinstuderende og læger.Denne 3. udgave er blevet grundigt opdateret og væsentlig forbedret med den nyeste viden og et væld af erfaringer fra klinisk praksis. Bogen indeholder kort og præcis information om de 100 mest solgte lægemiddelgrupper i Danmark. Bogen giver dig: lægemidlernes navne, hvilke sygdomme de bruges til at behandle, hvordan de virker, de vigtigste bivirkninger, særlige oplysninger.Bogen gennemgår desuden de 25 hyppigste problemer, som kan løses ved brug af håndkøbslægemidler, samt de vigtigste fakta om naturlægemidler, lægemiddelinteraktioner, receptlovgivningen og reglerne for tilskud til medicin.

We're battling Zoom fatigue. We're burnt out. We're a lost generation, clawing our way through endless economic permacrisis. The pharma industry, in response, has lunged towards digital transformations and omnichannel implementations, yet very little has improved as a result. In fact, it feels as though things have only gotten worse. The COVID pandemic has a lot to answer for, and the problems pharma faced as a result of the pandemic have only been compounded by this digital transformation. Many executives and field teams have found themselves lost amidst constant reorganisations, unsure how get back to the performance levels they had before. Enter The Omni Advantage by Mehrnaz Campbell, a beacon of clarity in this digital fog. Herein lies a vision for a future that is secure and effective. It urges leaders to rediscover the timeless currency of trust and authentic communication in a digital age. Campbell expertly guides professionals on how they can focus on what truly matters. Specifically, she shows them how to bypass the distractions of the shiny objects and how to home in on the meaningful human connections that have always formed the industry's cornerstone. With insightful examples and actionable advice, you have in your hands an essential ally for the commercial, medical, and marketing leaders who want to see beyond these turbulent times. It's a concise roadmap to rebuilding confidence, enhancing quality, and fostering genuine engagement in an industry poised for meaningful change. Seize the advantage-the Omni Advantage!

"Intellectual Property Rights in Pharmaceutical Industry: Theory and Practice" is an exclusive book shedding light on the fundamental concepts of intellectual property protection, with a special emphasis on pharmaceuticals. The book explores how the importance of intellectual property rights has grown in the last few decades, especially in India, after signing the World Trade Organisation agreement. The book explains how the Indian government has made necessary amendments in the intellectual property laws, built infrastructure, and even introduced topics related to intellectual property rights in the academic curriculum.The book dives deeply into the Indian patent system, with case studies from US and Indian courts serving as examples, to provide a better understanding of the system. The third edition is a result of the major administrative changes observed in the Indian government in recent years.This book is aimed at students, industry professionals, scientists, regulators, and policymakers interested in the pharmaceutical industry. This book serves as a valuable resource for B. Pharm, Pharm D, M. Pharm, and Ph.D. level students, along with other science educational programs in all the Universities of India. On reading this book, the pharmaceutical community will gain a better understanding of the intellectual property protection system, leading to an orientation of research development to ensure intellectual property protection.This book is a must-have for anyone involved in the pharmaceutical industry who wants to understand the nuances of intellectual property protection in India.

A complete market research guide to the business of biotechnology, drugs, diagnostics and genetics-for strategic planning, competitive intelligence, employment searches or financial research.

"The blistering inside story of a startup that made millions pushing opioids-until its cutthroat tactics were exposed and its executives put behind bars John Kapoor had amassed a small fortune in pharmaceuticals when he conceived of a new product. It was the 2000s, and opioids were big business. If Kapoor, an immigrant and the billionaire founder of Insys, could find a new way to administer the highly potent fentanyl, he could patent his invention and sell it to those in need-at a steep price. The only problem: There weren't enough people in need. Kapoor's drug was approved for breakthrough cancer pain. If Subsys was going to turn a profit, the company would need to persuade doctors to prescribe it "off-label," for other, lesser forms of pain. This is the story of how Insys turned a niche drug into big business. With executives leading the charge, Insys sales reps seduced doctors with charm, money, and sex. Its administrators lied to health care providers, claiming recipients had cancer when they did not. It pushed drugs onto patients that would have benefited from safer options, or no drugs at all. The strategy worked: When Insys went public, it notched the biggest IPO of its year. But several employees reached their limit and quietly blew the whistle, bringing the full force of the justice system upon the drug maker. In The Hard Sell, author and National Magazine Award-finalist Evan Hughes lays bare the pharma playbook. He shows how drug makers like Insys, fueled by greed and a hunger for market share, turn deception into profit. The book represents a stunning vindication, but also a cautionary tale. As Hughes shows, Insys didn't do anything its competitors weren't also doing. It was simply worse at covering its tracks"--

Our world is threatened by serious global climate changes and socioeconomic concerns.Most climate scientists agree that the major cause of the current global warming is the heatentrapped by the atmosphere, which is radiating from the earth into space; a phenomenon calledthe greenhouse effect (D. Lee & Brenner, 2015). Researchers have warned that carbon dioxideand other greenhouse gas emissions (water vapor, methane, and nitrous oxide) are at their highestlevel worldwide ever (Burney, Kennel, & Victor, 2013). The burning of fossil fuels such as coaland oil throughout the past century has increased the atmospheric concentration of carbondioxide. The amount of these gases released into the atmosphere in 2010 was 31% higher thanthe 1990. The increase in global temperatures as a result of climate change has far-reachingconsequences for human beings and the earth's ecosystems

This book covers computer-integrated equipment manufacturing, which allows high levels of adaptability and rapid equipment design changes to enable smart manufacturing processes. Benefits of the integration of lean manufacturing, smart sensors, 5G technology, IoTs, virtual reality, 3D printing, robotics and automation, are discussed.

How Big Pharma failed to end a pandemic, and what it tells us about the global economy

When COVID-19 erupted from Wuhan, China under mysterious circumstances, the Communist Party of China covered up its existence for as long as possible. It is now apparent that there is more to COVID than what the authorities wish for us to know. Biohacked: China’s Race to Control Life details the decades-long pursuit by the Chinese Communists to dominate the biotechnology industry—to control the very building blocks of life on Earth—to further their political control at home and their supremacy abroad. More appalling than the egregious cover-up that China’s rulers engaged in with COVID-19 is the fact that Western scientists, pharmaceutical companies, and research labs have contributed to China’s rapid (and dangerous) growth in the biotech industry—so much so that China, not the United States, may become the seat of the biotechnology industry. The Chinese leadership believes that biotechnology is a critical industry for the Communist Party to achieve its goal of becoming the world’s dominant superpower by 2049. In China’s biotech sector, truly macabre practices are being developed, from ambitious cloning programs to the creation of potential pathogens that China’s military plans to use in “specific genetic attacks” against Beijing’s growing list of political enemies.To stop the threat, author Brandon J. Weichert proposes the world’s nations create a comprehensive set of treaties for regulating biotechnology research and development. Further, Weichert calls for Washington to slow the transfer of advanced biotechnology knowledge and funding from the United States to China using means like the Foreign Corrupt Practices Act and the Committee on Foreign Investment in the United States (CFIUS). Unless an all-of-government (and society) approach is taken to curbing irresponsible biotech development in China, then another—deadlier—COVID-19-like pandemic could be at hand.

Mathematics for Physical Chemistry, Fifth Edition includes exercises that enable readers to test their understanding and put theory into practice. Chapters are constructed around a sequence of mathematical topics, progressing gradually into more advanced material, before discussing key mathematical skills, including the analysis of experimental data and-new to this edition-complex variables. Includes additional new content on Mathematica and its advanced applications. Drawing on the experience of its expert authors, this book is the ideal supplementary text for practicing chemists and students wanting to sharpen their mathematics skills and understanding of key mathematical concepts for applications across physical chemistry.

"El apellido Sackler adorna los muros de las instituciones mâas distinguidas: Harvard, el Metropolitan, Oxford, el Louvre... Es una de las familias mâas ricas del mundo, benefactora de las artes y las ciencias. El origen de su patrimonio siempre fue dudoso, hasta que saliâo a la luz que lo habâian multiplicado gracias a OxyContin, un potente analgâesico que catalizâo la crisis de los opioides en Estados Unidos. El imperio del dolor empieza en la Gran Depresiâon, con la historia de tres hermanos dedicados a la medicina: Raymond, Mortimer y el infatigable Arthur Sackler, dotado de una visiâon especial para la publicidad y el marketing. Aänos despuâes, contribuyâo a la primera fortuna familiar ideando la estrategia comercial de Valium, un revolucionario tranquilizante, para una gran farmacâeutica. Tras unas dâecadas fue Richard Sackler, el hijo de Raymond, quien pasâo a dirigir los negocios del clan, incluida Purdue Pharma, su propia empresa fabricante de medicamentos. Basâandose en las tâacticas agresivas de su tâio Arthur para vender el Valium, lanzâo un fâarmaco que habâia de ser definitivo: OxyContin. Con âel ganaron miles de millones de dâolares, pero terminarâia por arruinar su reputaciâon. Desde 2017, Patrick Radden Keefe ha investigado los secretos de la dinastâia Sackler: las complicadas relaciones familiares, los flujos de dinero, sus dudosas prâacticas corporativas... El resultado es una bomba periodâistica que relata el auge y declive de una de las grandes familias americanas y su oscuro emporio de la salud"--

This volume describes a career in pharmacy spanning the age of botanical mixtures from the corner drug store to modern large-scale pharmaceutical manufacturing. The author was born in New Haven, Connecticut in 1885, graduated from Yale's Sheffield Scientific School in 1904, and completed his Ph.D. in chemistry at Yale in 1908. As a student he clerked in retail drug stores, primarily one owned by his uncle, and became a licensed pharmacist. After finishing his Ph.D. he moved to Chicago, working at the U.S. Bureau of Chemistry which was just beginning to enforce the provisions of the Food and Drug Act of 1906. In 1913 he became the first chemist to work at the Upjohn Company in Kalamazoo, Michigan. He was director of research at the Upjohn Company from the time when he was the sole member of the department to when it employed dozens of active researchers covering a wide range of investigations. He developed several nationally-known pharmaceutical products, such as Digitora, Citrocarbonate, Super D Cod Liver Oil, Adrenal Cortical Extract, Sex Hormones, and Germicides, whose histories are described in separate chapters. The book concludes with a description of the early manufacturing successes for penicillin, when multiple private firms in the U.S. developed penicillin from an unstable, difficult to manufacture drug to a mass-produced low-cost product whose adoption and widespread use was unprecedented

From the thought leaders at Boston Consulting Group come lessons on how leading health systems around the world are delivering patient-centered, value-based care by focusing on the health outcomes that matter to patients.Delivering better health outcomes to patients for the money spent is an approach known as value-based health care. Contrary to traditional approaches to health-systems reform that emphasize cost containment, value-based health care shifts the focus to continuous improvement in the health outcomes delivered to patients. The premise of this approach is that systematically measuring, tracking, and improving health outcomes over time can have a transformative effect on the health care industry-enabling health systems to deliver better patient outcomes more consistently; to identify and disseminate best-practice treatments more rapidly; and to control total health-care costs more effectively because unnecessary procedures are eliminated, expensive complications occur less frequently, and repeat treatments are avoided. The only way for health systems to sustainably contain costs is by putting the patient and the delivery of outcomes that matter to patients at the center of the industry's efforts and by aligning incentives around the continuous improvement of health outcomes in a cost-effective manner.Featuring powerful case studies of leading value-based innovators in health systems all over the world-both public and private, as well as from both high- and low-income countries-this book is designed as a practical step-by-step guide for clinicians, payers, and policymakers alike to put these ideas into action. The Patient Priority will be an indispensable tool to launch a new era of patient-centered innovation, unlock value in health care, and accelerate the value-based transformation of the world's health systems, enabling improvements in productivity, performance, and population health.

The Path to Overcoming the Opioid Addiction Crisis For over twenty years, America's opioid addiction crisis has been spiraling out of control-and the COVID-19 pandemic just made matters worse. Even though billions of dollars are spent annually on substance use disorder (SUD) treatment, the patient numbers keep climbing-because of a misguided focus on episodic health emergencies rather than long-term care that's proven to be much more effective and cost-efficient. Clearly, it's time for a radically new approach, and in Unhooked, healthcare experts Chris Powell and Dr. Jill Warrington deliver just that. Their new revolutionary holistic care strategy is built around a multipronged policy that: - removes the stigma of opioid addiction by treating it as a chronic illness, not human weakness; - leverages data and analytics to provide more comprehensive individual care; - removes common barriers to recovery; - reduces the cost of care; - creates equity for SUD and behavioral health management; and - identifies prevention strategies that can block disease progression. Most importantly, Powell and Warrington outline a practical step-by-step strategy to inspire and implement change in your organization. If society is truly to become unhooked, this book provides a proven path to wellness that can get the job done.

Wall Street Journal Bestseller2022 Genesis Prize LaureateThe exclusive, first-hand, behind-the-scenes story of how Pfizer raced to create the first Covid-19 vaccine, told by Pfizer's Chairman and CEO Dr. Albert Bourla.A riveting, fast-paced, inside look at one of the most incredible private sector achievements in history, Moonshot recounts the intensive nine months in 2020 when the scientists at Pfizer, under the visionary leadership of Dr. Albert Bourla, made ?the impossible possible??creating, testing, and manufacturing a safe and effective Covid-19 vaccine that previously would have taken years to develop. Dr. Bourla chronicles how the brilliant, dedicated minds at Pfizer, under the enormous strains of the global pandemic, overcame a series of crises that were compounded by social and political unrest, and reveals the doubts, decisions, obstacles, and failures they encountered. As Dr. Bourla makes clear, Pfizer's success wasn't due to luck; it was because of preparation driven by four simple values?Courage, Excellence, Equity, and Joy.Moonshot is a story of leadership under the most unprecedented circumstances?how Dr. Bourla, a Greek immigrant, a child of Holocaust survivors, and a veterinarian, became the head of one of the world's largest corporations and initiated a dramatic transformation of the organization just before a global health crisis would serve to test the organization, its scientists, and its leader, like never before. Moonshot describes best practices that can be used to address the multiple, unprecedented challenges our world faces, reveals Pfizer's implementation of scientific breakthroughs at a record-breaking pace, and offers leadership lessons that can help anyone successfully manage their own seemingly unsolvable problems. As Dr. Bourla explains, ?I am sharing the story of our moonshot?the challenges we faced, the lessons we learned, and the core values that allowed us to make it happen?in hopes that it might inspire and inform your own moonshot, whatever that may be.?

At the early project stages of plant construction, cost estimates for projects in the process industry are a prerequisite for gaining a competitive advantage in a global market with increasing commodity prices, engineering and installation costs. This book gives readers a detailed overview of the structure of cost estimates in brownfield and greenfield plant projects and the method of preparing the required accompanying documentation. Using a project example, the book presents a cost estimate with different levels of accuracy. The attachment comprises cost estimation templates and corresponding documents that can also be ordered separately from the publisher as Word and Excel files.. Basics of cost estimation. Cost estimation types, classes and methods. Planning (engineering). Equipment and material procurement. Installation and construction. Exemplary templates

Valideringshåndbogen er en praktisk vejledning i forståelse og udførelse af valideringsaktiviteter i den farmaceutiske og medicinske industri. Bogen henvender sig til personer, der kommer i berøring med emnet validering. Begrebet »validering« har haft en tendens til at blive opfattet som noget indviklet og måske besværligt, derfor afmystificerer forfatteren begrebet og gør emnet til noget, der kan arbejdes med i praksis.Bogen indeholder hele grundlaget for valideringsarbejde, der er baseret på kvaliteten af det, som valideres.Definitionen af begrebet kvalitet er »opfyldelse af forventninger«, så de aktiviteter, der foretages og forventes, lever op til denne norm. Det handler Valideringshåndbogen også om!